ArticleFrontiers in pain research (Lausanne, Switzerland)2026
OPRM1 gene polymorphism linked to anxiety in cancer-related pain patients: an observational study.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anxiety is common in patients with cancer-related pain, affecting an increasing number of individuals annually and negatively impacting prognosis. Limited methods are available for early identification of anxiety in these patients. This study explores the link between the OPRM1 gene's polymorphism and anxiety in cancer patients. Methods: We prospectively recruited 76 patients experiencing pain from Yunfu People's Hospital and assessed them with questionnaires on anxiety, depression, quality of life, and other metrics before they commenced opioid treatment. Additionally, Numeric Rating Scale (NRS) scores and opioid usage data were recorded. In situ hybridization was used to analyze the OPRM1 polymorphism rs1799971. Based on the available data, appropriate opioid dosage conversion relationships were established. Results: This study found that 40.8% (31/76) exhibited anxiety symptoms. OPRM1 genotyping revealed 31.6% AA, 48.7% AG, and 19.7% GG genotypes, conforming to Hardy-Weinberg equilibrium. No genotype differences were found in morphine dosage or NRS pain scores. However, G allele carriers exhibited significantly lower anxiety scores (median 27.0 vs. 36.0, Discussion: Our study indicates that G allele carriers exhibit lower anxiety levels, suggesting a certain correlation between the OPRM1 gene polymorphism and anxiety in cancer pain patients. Furthermore, there is a need to pay increased attention to the psychological health of cancer pain patients with the AA genotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.